本帖最后由 橙色雨丝 于 2015-4-24 06:37 编辑
Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOGand LYSA Studies. 低血清维生素D水平与滤泡性淋巴瘤较差生存率相关:SWAG和LYSA研究中的一项前瞻性的评估
Kelly JL1, Salles G1, Goldman B1, Fisher RI1, Brice P1, Press O1, Casasnovas O1, Maloney DG1, Soubeyran P1, Rimsza L1, Haioun C1, Xerri L1, LeBlanc M1, Tilly H1, Friedberg JW2.
Abstract 摘要
PURPOSE: 目的
Recent literature reports a potential association between high vitamin D and improved lymphoma prognosis. We evaluated the impact of pretreatment vitamin D on follicular lymphoma (FL)outcome. 最近有文献报道较高维生素D和较好的淋巴瘤预后有潜在联系。我们分析了治疗前的维生素D水平对滤泡性淋巴瘤预后的影响
PATIENTS AND METHODS:患者与方法
SWOG participants were previously untreated patients with FL enrolled onto SWOG clinical trials (S9800, S9911, or S0016)involving CHOP chemotherapy plus an anti-CD20 antibody (rituximab or iodine-131tositumomab) between 1998 and 2008. Participants included in our second independent cohort were also previously untreated patients with FL enrolled onto the Lymphoma Study Association (LYSA) PRIMA trial of rituximab plus chemotherapy (randomly assigned to rituximab maintenance v observation) between2004 and 2007. SWAG临床研究的参加者是滤泡性淋巴瘤患者,在1998-2008年之间初治接受了CHOP加抗CD20单抗(美罗华或者是托西莫单抗)的治疗。我们第二个独立的研究组别的参加者包括参加PRIMA临床研究的初治滤泡性淋巴瘤患者,在2004-2007年之间接受了美罗华联合化疗(之后随机选择美罗华维持或观察)。
Using the gold-standard liquidchromatography-tandem mass spectrometry method, 25-hydroxyvitamin D was measured in stored baseline serum samples. The primary end point was progression-free survival (PFS). 采用金标准液相色谱-串联质谱法,对存储的基准血清样本的25羟基维生素D进行了测量。研究的主要主要终点为无进展生存率。
RESULTS: 结果
After a median follow-up of 5.4 years, the adjusted PFS and overall survival hazard ratios for the SWOG cohort were 1.97(95% CI, 1.10 to 3.53) and 4.16 (95% CI, 1.66 to 10.44), respectively, for those who were vitamin D deficient (< 20 ng/mL; 15% of cohort). After amedian follow-up of 6.6 years, the adjusted PFS and overall survival hazard ratios for the LYSA cohort were 1.50 (95% CI, 0.93 to 2.42) and 1.92 (95% CI, 0.72 to5.13), respectively, for those who were vitamin D deficient (< 10 ng/mL; 25%of cohort). 在中位随访5.4年之后,经调整的无进展生存率和总生存率的风险比在SWAG组分别为1.97(95% CI, 1.10 to 3.53)和4.16(95% CI, 1.66 to 10.44),组内维生素D缺乏的约占15%,定义为维生素D水平小于20ng/mL。在中位随访6.6年后,经调整的无进展生存率和总生存率的风险比在LYSA组分别是1.5(95% CI, 0.93 to 2.42)和1.92(95% CI, 0.72 to 5.13),组内25%维生素D缺乏,定义为维生素D水平小于10ng/mL。
CONCLUSION: 结论
Although statistical significance was not reached in the LYSA cohort, the consistent estimates of association between low vitamin D levels and FL outcomes in two independent cohorts suggests that serum vitamin D might be the first potentially modifiable factor to be associated with FL survival. Further investigation is needed to determine the effects ofvitamin D supplementation in this clinical setting. 尽管LYSA组的数据尚未达到统计学意义,但是在两个相互独立的研究组中获得了关于低维生素D与不良预后相关的一致性的初步结论提示血清中维生素D水平可能是潜在的可以改变滤泡性淋巴瘤生存率的因素。需要通过进一步的研究在临床上确定补充维生素D的作用。
© 2015 by American Society of ClinicalOncology. 美国临床肿瘤2015年
|